Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Benzinga readers can review the latest analyst takes on their favorite stocks by visiting Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy.

Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.

Organon & Co. OGN

Dividend Yield: 7.24%
Morgan Stanley analyst Terence Flynn maintained an Equal-Weight rating and cut the price target from $17 to $16 on Feb. 14. This analyst has an accuracy rate of 68%.
Piper Sandler analyst David Amsellem maintained an Overweight rating and raised the price target from $22 to $24 on April 29, 2024. This analyst has an accuracy rate of 71%.
Recent News: On Feb. 13, Organon reported better-than-expected fourth-quarter adjusted EPS results.
Benzinga Pro’s real-time newsfeed alerted to latest OGN news.

Pfizer Inc. PFE

Dividend Yield: 6.73%
Guggenheim analyst Vamil Divan reiterated a Buy rating with a price target of $33 on Feb. 10, 2025. This analyst has an accuracy rate of 76%.
Citigroup analyst Andrew Baum maintained a Neutral rating and cut the price target from $30 to $29 on Jan. 28, 2025. This analyst has an accuracy rate of 70%.
Recent News: On Feb. 13, Pfizer reported Phase 3 TALAPRO-2 study results.
Benzinga Pro's real-time newsfeed alerted to latest PFE news

Bristol-Myers Squibb Company BMY

Dividend Yield: 4.56%
Wells Fargo analyst Mohit Bansal maintained an Equal-Weight rating and raised the price target from $60 to $62 on Feb. 7, 2025. This analyst has an accuracy rate of 72%.
Citigroup analyst Andrew Baum maintained a Neutral rating and boosted the price target from $60 to $65 on Jan. 28, 2025. This analyst has an accuracy rate of 70%.
Recent News: On Feb. 19, Bristol Myers Squibb announced the final analysis of overall survival from the Phase 3 Checkmate -816 study, which evaluated Opdivo (Nivolumab) in combination with platinum-doublet chemotherapy as a neoadjuvant treatment for adult patients with resectable (Tumors ≥ 4 cm or node positive) non-small cell lung cancer.
Benzinga Pro’s real-time newsfeed alerted to latest BMY news